CLOROX CO /DE/, 10-Q filed on 5/5/2025
Quarterly Report
v3.25.1
Cover Page - shares
 9 Months Ended
Mar. 31, 2025
Apr. 21, 2025
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2025  
Document Transition Report false  
Entity File Number 1-07151  
Entity Registrant Name THE CLOROX COMPANY  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 31-0595760  
Entity Address, Address Line One 1221 Broadway  
Entity Address, City or Town Oakland  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94612-1888  
City Area Code 510  
Local Phone Number 271-7000  
Title of 12(b) Security Common Stock - $1.00 par value  
Trading Symbol CLX  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   123,252,807
Entity Central Index Key 0000021076  
Amendment Flag false  
Current Fiscal Year End Date --06-30  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2025  
v3.25.1
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]        
Net sales $ 1,668 $ 1,814 $ 5,116 $ 5,190
Cost of products sold 924 1,048 2,827 3,026
Gross profit 744 766 2,289 2,164
Selling and administrative expenses 267 301 828 899
Advertising costs 207 215 599 566
Research and development costs 27 32 89 93
Loss on divestiture 0 240 118 240
Pension settlement charge 0 0 0 171
Interest expense 23 22 66 69
Other (income) expense, net (34) (2) (79) 3
Earnings (losses) before income taxes 254 (42) 668 123
Income tax expense 63 8 180 52
Net earnings (losses) 191 (50) 488 71
Less: Net earnings attributable to noncontrolling interests 5 1 10 7
Net earnings (losses) attributable to Clorox $ 186 $ (51) $ 478 $ 64
Net earnings per share attributable to Clorox        
Basic net earnings (losses) per share (in dollars per share) $ 1.51 $ (0.41) $ 3.87 $ 0.52
Diluted net earnings (losses) per share (in dollars per share) $ 1.50 $ (0.41) $ 3.84 $ 0.52
Weighted average shares outstanding (in thousands)        
Basic (in shares) 123,367 124,249 123,643 124,133
Diluted (in shares) 124,066 124,249 124,468 124,721
Comprehensive income $ 196 $ 154 $ 467 $ 409
Less: Total comprehensive income attributable to noncontrolling interests 5 1 10 7
Total comprehensive income attributable to Clorox $ 191 $ 153 $ 457 $ 402
v3.25.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2025
Jun. 30, 2024
Current assets    
Cash and cash equivalents $ 226 $ 202
Receivables, net 597 695
Inventories, net 635 637
Prepaid expenses and other current assets 132 88
Total current assets 1,590 1,622
Property, plant and equipment, net of accumulated depreciation and amortization of $2,872 and $2,821, respectively 1,245 1,315
Operating lease right-of-use assets 349 360
Goodwill 1,222 1,228
Trademarks, net 501 538
Other intangible assets, net 68 143
Other assets 537 545
Total assets 5,512 5,751
Current liabilities    
Notes and loans payable 54 4
Current operating lease liabilities 85 84
Accounts payable and accrued liabilities 2,016 1,486
Total current liabilities 2,155 1,574
Long-term debt 2,483 2,481
Long-term operating lease liabilities 322 334
Other liabilities 341 848
Deferred income taxes 21 22
Total liabilities 5,322 5,259
Commitments and contingencies
Stockholders’ equity    
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding 0 0
Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of March 31, 2025 and June 30, 2024; and 123,251,595 and 124,201,807 shares outstanding as of March 31, 2025 and June 30, 2024, respectively 131 131
Additional paid-in capital 1,304 1,288
Retained earnings 99 250
Treasury stock, at cost: 7,489,866 and 6,539,654 shares as of March 31, 2025 and June 30, 2024, respectively (1,331) (1,186)
Accumulated other comprehensive net (loss) income (176) (155)
Total Clorox stockholders’ equity 27 328
Noncontrolling interests 163 164
Total stockholders’ equity 190 492
Total liabilities and stockholders’ equity $ 5,512 $ 5,751
v3.25.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2025
Jun. 30, 2024
Statement of Financial Position [Abstract]    
Property, plant and equipment, accumulated depreciation and amortization $ 2,872 $ 2,821
Preferred stock, par value (in dollars per share) $ 1.00 $ 1.00
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 1.00 $ 1.00
Common stock, shares authorized (in shares) 750,000,000 750,000,000
Common stock, shares issued (in shares) 130,741,461 130,741,461
Common stock, shares outstanding (in shares) 123,251,595 124,201,807
Treasury stock (in shares) 7,489,866 6,539,654
v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating activities:    
Net earnings $ 488 $ 71
Adjustments to reconcile net earnings to net cash provided by operations:    
Depreciation and amortization 162 176
Stock-based compensation 64 55
Deferred income taxes (16) (126)
Loss on divestiture 112 238
Pension settlement charge 0 171
Other (9) 18
Changes in:    
Receivables, net 71 (16)
Inventories, net (54) 20
Prepaid expenses and other current assets (28) 12
Accounts payable and accrued liabilities (87) (120)
Operating lease right-of-use assets and liabilities, net 1 0
Income taxes payable / prepaid (17) (144)
Net cash provided by operations 687 355
Investing activities:    
Capital expenditures (145) (131)
Proceeds from divestiture, net of cash divested 128 17
Other (1) 20
Net cash used for investing activities (18) (94)
Financing activities:    
Notes and loans payable, net 50 61
Treasury stock purchased (257) 0
Cash dividends paid to Clorox stockholders (452) (446)
Cash dividends paid to noncontrolling interests (16) 0
Issuance of common stock for employee stock plans and other 30 3
Net cash used for financing activities (645) (382)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (2) (26)
Net increase (decrease) in cash, cash equivalents and restricted cash 22 (147)
Cash, cash equivalents and restricted cash:    
Beginning of period 207 368
End of period $ 229 $ 221
v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The unaudited interim condensed consolidated financial statements for the three and nine months ended March 31, 2025 and 2024, in the opinion of management, reflect all normal and recurring adjustments considered necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company or Clorox) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. Percentage and basis point calculations are based on rounded numbers, except for per share data and the effective tax rate.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2024, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.
Recently Issued Accounting Standards
Recently Issued Accounting Standards Not Yet Adopted
In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” These amendments primarily require enhanced quantitative and qualitative disclosures in the notes to the financial statements for specific expense categories underlying the expenses presented on the income statement. These amendments are to be applied prospectively to financial statements issued after the effective date or retrospectively to any or all periods presented in the financial statements. Early adoption is permitted. The standard will be effective for annual periods beginning after December 15, 2026, and subsequent interim periods. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” These amendments primarily require enhanced disclosures and disaggregation of income tax information by jurisdiction in the annual income tax reconciliation and quantitative and qualitative disclosures regarding income taxes paid. These amendments are to be applied prospectively, with the option to apply the standard retrospectively, for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments primarily require enhanced disclosures about significant segment expenses regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. These amendments are to be applied retrospectively for all periods presented in the financial statements and will be effective for the annual period beginning July 1, 2024, and interim periods beginning July 1, 2025. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
Recently Adopted Accounting Standards
In September 2022, the FASB issued ASU No. 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” These amendments require disclosure of the key terms of outstanding supplier finance programs and a rollforward of the related obligations. These amendments are effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted the standard as of July 1, 2023, except for the rollforward information which will be effective for the fiscal year ending June 30, 2025. The adoption relates to disclosures only and does not have an impact on the condensed consolidated financial statements, results of operations or cash flows.
v3.25.1
VENTURE AGREEMENT
 9 Months Ended
Mar. 31, 2025
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
VENTURE AGREEMENT VENTURE AGREEMENT
The Company has an agreement with The Procter & Gamble Company (P&G) for the Company’s Glad bags and wraps business. In connection with this agreement, P&G provides research and development (R&D) support to the Glad business. As of both March 31, 2025 and June 30, 2024, P&G had a 20% interest in the venture. The Company pays a royalty to P&G for its interest in the profits, losses and cash flows, as contractually defined, of the Glad business, which is included in Cost of products sold.
The term of this agreement was to expire in January 2026, unless the parties agreed, on or prior to January 31, 2025, to further extend the term of the agreement for another seven years or agree to take some other relevant action. Since the parties jointly did not opt to further extend the term of the agreement for another seven years or agree to take some other relevant action on or before January 31, 2025, the agreement will terminate in accordance with its terms in January 2026.
Upon termination of the agreement, the Company is required to purchase P&G’s 20% interest for cash at fair value as established by predetermined valuation procedures. As of March 31, 2025, the estimated fair value of P&G’s interest was $476, of which $515 was recognized and reflected in Accounts payable and accrued liabilities as it is reasonably expected to be settled within one year. As of June 30, 2024, the estimated fair value of P&G’s interest was $531, of which $510 was recognized and reflected in Other liabilities. The difference between the estimated fair value and the amount recognized, and any future changes in the fair value of P&G’s interest, is charged to Cost of products sold in accordance with the effective interest method over the remaining life of the agreement. Following termination, the Glad business will retain the exclusive core intellectual property licenses contributed by P&G on a royalty-free basis for the licensed products marketed.
v3.25.1
DIVESTITURES
 9 Months Ended
Mar. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
DIVESTITURES DIVESTITURES
Divestiture of Better Health Vitamins, Minerals and Supplements (VMS) Business
On September 10, 2024, the Company completed the divestiture of its Better Health VMS business in its entirety to an affiliate of Piping Rock Health Products, LLC. The divested business includes the Natural Vitality, NeoCell, Rainbow Light and RenewLife brands, relevant trademarks and licenses, and associated manufacturing and distribution facilities in Sunrise, Florida. The transaction reflects the Company’s commitment to continue evolving its portfolio to reduce volatility and accelerate sales growth, as well as structurally improve its margin, in service of driving more consistent and profitable growth over time. The transaction was executed pursuant to a purchase agreement. As a result of the transaction, the Company recorded an after tax loss of $118 during the nine months ended March 31, 2025.
The major classes of assets and liabilities of the Better Health VMS business divested as of September 10, 2024 were as follows:
Divestiture
Working capital, net$41 
Property, plant and equipment, net59 
Trademarks, net
37 
Other intangible assets, net
58 
Other assets (1)
45 
Other liabilities(1)
Net assets divested$239 
(1) Includes net deferred tax assets of $45
The following table presents Net sales of the Better Health VMS business, which includes the financial results up to September 10, 2024, the date of sale:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Net sales
$— $54 $38 $166 
The divestiture of the Company’s Better Health VMS business does not meet the criteria to be reported as discontinued operations in the condensed consolidated financial statements as the Company’s decision to divest this business did not represent a strategic shift that will have a major effect on the Company’s operations and financial results.
Divestiture of Argentina Business
On March 20, 2024, the Company completed the divestiture of its Argentina business. As a result of the transaction, the Company recorded a pre-tax loss of $240 during the third quarter of fiscal year 2024. Net sales of the Argentina business for the three and nine months ended March 31, 2024 were $43 and $123, respectively. Refer to Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024 for further information related to the Argentina business divestiture.
v3.25.1
AUGUST 2023 CYBERATTACK
 9 Months Ended
Mar. 31, 2025
Unusual or Infrequent Items, or Both [Abstract]  
AUGUST 2023 CYBERATTACK AUGUST 2023 CYBERATTACK
On Monday, August 14, 2023, the Company identified unauthorized activity on some of its Information Technology (IT) systems and immediately began taking steps to stop and remediate the activity. The Company took certain systems offline, engaged third-party cybersecurity experts and implemented its business continuity plans. However, the incident resulted in wide-scale disruptions to the Company’s business operations. The impacts of these system disruptions resulted in a negative impact on net sales and earnings. The Company experienced lessening operational impacts in the second quarter of fiscal year 2024 and has since returned to normalized operations.
The Company recorded insurance recoveries of $35 and $70 in the three and nine months ended March 31, 2025, respectively, and incurred incremental expenses of approximately $8 and $57 in the three and nine months ended March 31, 2024, respectively, as a result of the cyberattack. The following table summarizes the recognition of (insurance recoveries) and costs in the condensed consolidated statements of earnings and comprehensive income:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Costs of products sold
$(2)$1 $(5)$21 
Selling and administrative expenses— 7 — 36 
Other (income) expense, net
(33)— (65)— 
Total$(35)$8 $(70)$57 
The costs incurred related primarily to third-party consulting services, including IT recovery and forensic experts and other professional services incurred to investigate and remediate the attack, as well as incremental operating costs incurred from the resulting disruption to the Company’s business operations. The Company does not expect to incur significant costs related to the cyberattack in future periods. No additional insurance recoveries related to the cyberattack are anticipated. Insurance recoveries are classified consistent with the expenses to which they relate. Business interruption and other insurance recoveries that do not correspond directly to previously incurred expenses are recognized in Other (income) expense, net.
v3.25.1
SUPPLY CHAIN FINANCING PROGRAM
 9 Months Ended
Mar. 31, 2025
Payables and Accruals [Abstract]  
SUPPLY CHAIN FINANCING PROGRAM SUPPLY CHAIN FINANCING PROGRAM
The Company has arranged for a global financial institution to offer a voluntary supply chain finance (SCF) program for the benefit of the Company’s suppliers. The Company’s current payment terms do not exceed 120 days in keeping with industry standards. The Company’s operating cash flows are directly impacted as a result of the extension of payment terms with suppliers. The SCF program enables suppliers to directly contract with the financial institution to receive payment from the financial institution prior to the payment terms between the Company and the supplier by selling the Company’s payables to the financial institution. Participation in the program is at the sole discretion of the supplier and the Company has no economic interest in a supplier's decision to enter into the agreement and has no direct financial relationship with the financial institution, as it relates to the SCF program. Once a supplier elects to participate in the SCF program and reaches an agreement with the financial institution, the supplier elects which individual Company invoices to sell to the financial institution. The terms of the Company’s payment obligations are not impacted by a supplier’s participation in the program and as such, the SCF program has no direct impact on the Company’s balance sheets or liquidity. The Company has not pledged any assets as security or provided guarantees under the SCF program.
All outstanding amounts related to suppliers participating in the SCF program are recorded within Accounts payable and accrued liabilities in the condensed consolidated balance sheets and the associated payments are included in operating activities within the condensed consolidated statements of cash flows. As of March 31, 2025 and June 30, 2024, the amount due to suppliers participating in the SCF program and included in Accounts payable and accrued liabilities was $227 and $205, respectively.
v3.25.1
RESTRUCTURING AND RELATED COSTS
 9 Months Ended
Mar. 31, 2025
Restructuring and Related Activities [Abstract]  
RESTRUCTURING AND RELATED COSTS RESTRUCTURING AND RELATED COSTS
Beginning in the first quarter of fiscal year 2023, the Company recognized costs related to a plan that involves streamlining its operating model to meet its objectives of driving growth and productivity. The implementation of this new model was completed in fiscal year 2024 and is expected to enhance the Company’s ability to respond more quickly to changing consumer behaviors and innovate faster.
The total restructuring and related implementation costs, net associated with the Company’s streamlined operating model as reflected in the condensed consolidated statements of earnings and comprehensive income:
Three months endedNine months ended
3/31/20243/31/2024
Selling and administrative expenses$5 $8 
Other (income) expense, net:
Employee-related costs$5 $5 
Total costs$10 $13 
The following table reconciles the accrual for the streamlined operating model’s restructuring and related implementation costs discussed above, which are recorded within Accounts payable and accrued liabilities in the condensed consolidated balance sheets:
Employee-Related CostsOtherTotal
Accrual Balance as of June 30, 2024
$8 $11 $19 
Cash payments(8)(11)(19)
Accrual Balance as of March 31, 2025$— $— $— 
The Company may, from time to time, decide to pursue additional restructuring-related initiatives that involve costs in future periods.
Refer to Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024 for further information related to the streamlined operating model.
v3.25.1
INVENTORIES, NET
 9 Months Ended
Mar. 31, 2025
Inventory Disclosure [Abstract]  
INVENTORIES, NET INVENTORIES, NET
Inventories, net consisted of the following as of:
3/31/20256/30/2024
Finished goods$553 $556 
Raw materials and packaging145 172 
Work in process21 9 
LIFO allowances(84)(98)
Total inventories, net$635 $639 
Less: Non-current inventories, net (1)
— 2 
Total current inventories, net$635 $637 
(1)Non-current inventories, net are recorded in Other assets.
v3.25.1
DEBT
 9 Months Ended
Mar. 31, 2025
Debt Disclosure [Abstract]  
DEBT DEBT
Short-term borrowings
The weighted average effective interest rate of notes and loans payable as of March 31, 2025 and June 30, 2024 was 4.59% and 5.60%, respectively.
Credit arrangements
On March 25, 2025, the Company entered into a new $1,200 revolving credit agreement (the Credit Agreement) that matures in March 2030. The Credit Agreement replaced a prior $1,200 revolving credit agreement (the Prior Credit Agreement) in place since March 2022. The Company did not incur any termination fees or penalties in connection with entering the new agreement, which was considered a debt modification. There were no borrowings under either the Credit Agreement or the Prior Credit Agreement as of March 31, 2025 and June 30, 2024, respectively, and the Company believes that borrowings under the new Credit Agreement will continue to be available for general corporate purposes. The Credit Agreement includes certain restrictive covenants and limitations consistent with the previous agreement, with which the Company was in compliance as of March 31, 2025
v3.25.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
 9 Months Ended
Mar. 31, 2025
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]  
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Financial Risk Management and Derivative Instruments
The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.
Commodity Price Risk Management
The Company may use commodity futures, options and swap contracts to limit the impact of price volatility on a portion of its forecasted raw material requirements. These commodity derivatives may be exchange traded or over-the-counter contracts and generally have original contractual maturities of less than 2 years. Commodity purchase and options contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.
The notional amounts of outstanding commodity derivatives, which related primarily to exposures in soybean oil used for the food business and jet fuel used for the grilling business, were $27 and $38 as of March 31, 2025 and June 30, 2024, respectively.
Foreign Currency Risk Management
The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have original contractual maturities of less than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.
The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $37 and $29 as of March 31, 2025 and June 30, 2024, respectively.
Interest Rate Risk Management
The Company may enter into over-the-counter interest rate contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt. These interest rate contracts generally have original contractual maturities of less than 3 years. The interest rate contracts are measured at fair value using information quoted by bond dealers.
The Company held no interest rate contracts as of both March 31, 2025 and June 30, 2024.
Commodity, Foreign Exchange and Interest Rate Derivatives
The Company designates its commodity forward, futures and options contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate contracts for forecasted interest payments as cash flow hedges.
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings (losses) were as follows:
Gains (losses) recognized in Other comprehensive (loss) income
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Commodity purchase derivative contracts$1 $— $(2)$(5)
Foreign exchange derivative contracts(1)2 1 1 
Total$— $2 $(1)$(4)

Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earningsGains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Commodity purchase derivative contractsCost of products sold$(2)$(2)$(5)$(4)
Interest rate derivative contractsInterest expense4 4 10 10 
Total$2 $2 $5 $6 
The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of March 31, 2025 that is expected to be reclassified into Net earnings within the next twelve months is $12.
Counterparty Risk Management and Derivative Contract Requirements
The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions, $0 contained such terms as of both March 31, 2025 and June 30, 2024. As of both March 31, 2025 and June 30, 2024, neither the Company nor any counterparty was required to post any collateral as no counterparty liability position limits were exceeded.
Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the Company’s credit ratings, as assigned by Standard & Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both March 31, 2025 and June 30, 2024, the Company and each of its counterparties had been assigned investment grade ratings by both Standard & Poor’s and Moody’s.
Certain of the Company’s exchange traded futures and options contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of both March 31, 2025 and June 30, 2024, the Company maintained cash margin balances related to exchange traded futures and options contracts of $1 and $3, respectively, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.
Trust Assets
The Company holds interests in mutual funds and cash equivalents as part of trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which their compensation deferrals are invested in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and therefore trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The gains and losses on the trust assets are recorded in Other (income) expense, net in the condensed consolidated statements of earnings and comprehensive income. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.
Fair Value of Financial Instruments
Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.
As of both March 31, 2025 and June 30, 2024, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis during the period included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
 3/31/20256/30/2024
Balance sheet
classification		Fair value
hierarchy
level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Commodity purchase futures contracts
Prepaid expenses and other current assets1$1 $1 $— $— 
Commodity purchase swaps contractsPrepaid expenses and other current assets2— — 1 1 
Foreign exchange forward contractsPrepaid expenses and other current assets21 1 — — 
 $2 $2 $1 $1 
Liabilities
Commodity purchase futures contractsAccounts payable and accrued liabilities1$— $— $2 $2 
Commodity purchase swaps contractsAccounts payable and accrued liabilities21 1 — — 
$1 $1 $2 $2 
The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
 3/31/20256/30/2024
Balance sheet
classification		Fair value
hierarchy
level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Interest-bearing investments, including money market funds
Cash and cash
equivalents (1)
1$99 $99 $95 $95 
Time deposits
Cash and cash
equivalents (1)
214 14 9 9 
Trust assets for nonqualified deferred compensation plansOther assets1157 157 154 154 
 $270 $270 $258 $258 
Liabilities
Notes and loans payable
Notes and loans payable (2)
2$54 $54 $4 $4 
Long-term debt
Long-term debt (3)
22,483 2,407 2,481 2,341 
$2,537 $2,461 $2,485 $2,345 
(1)Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Notes and loans payable are composed of outstanding U.S. commercial paper balances and/or amounts drawn on the Company’s credit agreements, all of which are recorded at cost, which approximates fair value.
(3)Long-term debt is recorded at cost. The fair value of Long-term debt was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
v3.25.1
OTHER (INCOME) EXPENSE, NET
 9 Months Ended
Mar. 31, 2025
Other Income and Expenses [Abstract]  
OTHER (INCOME) EXPENSE, NET OTHER (INCOME) EXPENSE, NET
The major components of Other (income) expense, net were:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Amortization of trademarks and other intangible assets$5 $7 $16 $22 
Trust investment (gains) losses, net2 (8)(6)(18)
Net periodic benefit cost
3 1 — 11 
Foreign exchange transaction (gains) losses, net (1)
(1)1 2 24 
Income from equity investees— (1)(3)(3)
Interest income(2)(4)(7)(21)
Restructuring costs (2)
— 5 — 5 
Gain on sale-leaseback transaction (3)
— — — (16)
Cyberattack insurance recoveries (4)
(33)— (65)— 
Other(8)(3)(16)(1)
Total$(34)$(2)$(79)$3 
(1)Foreign exchange losses were primarily related to the Company’s operations in Argentina in the three and nine months ended March 31, 2024.
(2)Restructuring costs related to the implementation of the Company’s streamlined operating model. See Note 6 for additional details.
(3)On December 14, 2023, the Company completed an asset sale-leaseback transaction on a warehouse in Fairfield, California. The transaction resulted in a $16 gain which was recognized in Other (income) expense, net in the Health and Wellness segment. Refer to Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024 for further information related to the sale-leaseback transaction.
(4)Insurance recoveries related to the August 2023 cyberattack. See Note 4 for additional details.
v3.25.1
INCOME TAXES
 9 Months Ended
Mar. 31, 2025
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
In determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings was 24.8% and 26.9% for the three and nine months ended March 31, 2025, respectively, and the effective tax rate on (losses) earnings was (18.6)% and 41.9% for the three and nine months ended March 31, 2024, respectively. The change in tax rate on earnings in the current three month period as compared to the prior period was primarily driven by the divestiture of the Argentina business and a legal entity reorganization both in the prior period. The change in tax rate on earnings in the current nine month period as compared to the prior period was primarily driven by the divestiture of the Argentina business and a legal entity reorganization both in the prior period, and the nondeductibility of the loss on the divestiture of the Better Health VMS business in the current period.
Income taxes paid, net of refunds, were $208 and $314 for the nine months ended March 31, 2025 and 2024, respectively. The lower tax payments in the current nine-month period were primarily driven by payments of fiscal year 2023 income taxes in fiscal year 2024, that were previously deferred as a result of the relief provided by the IRS announced in January 2023 due to winter storms in California.
v3.25.1
NET EARNINGS (LOSSES) PER SHARE (EPS)
 9 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
NET EARNINGS (LOSSES) PER SHARE (EPS) NET EARNINGS (LOSSES) PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Basic123,367124,249123,643124,133
Dilutive effect of stock options and other699—825588
Diluted124,066124,249124,468124,721
Antidilutive stock options and other1,5754,758 1,575 2,720 
Basic net earnings per share and Diluted net earnings (losses) per share are calculated on Net earnings attributable to Clorox.
Since the Company generated net losses attributable to Clorox for the three months ended March 31, 2024, there was no dilutive effect of stock options and other instruments during this period because their impacts would be antidilutive.
v3.25.1
COMPREHENSIVE INCOME
 9 Months Ended
Mar. 31, 2025
Stockholders' Equity Note [Abstract]  
COMPREHENSIVE INCOME COMPREHENSIVE INCOME
The following table provides a summary of Comprehensive income for the periods indicated:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Net earnings (losses)$191 $(50)$488 $71 
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments7 206 (13)212 
Net unrealized gains (losses) on derivatives(2)(1)(7)(10)
Pension and postretirement benefit adjustments— (1)(1)136 
Total other comprehensive (loss) income, net of tax5 204 (21)338 
Comprehensive income
196 154 467 409 
Less: Total comprehensive income attributable to noncontrolling interests5 1 10 7 
Total comprehensive income attributable to Clorox
$191 $153 $457 $402 
v3.25.1
STOCKHOLDERS' EQUITY
 9 Months Ended
Mar. 31, 2025
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Changes in the components of Stockholders’ equity were as follows for the periods indicated:
Three months ended March 31
(Dollars in millions except per share data; shares in thousands)
Common stockAdditional paid-in capitalRetained earningsTreasury stockAccumulated
other
comprehensive
net (loss) income		Noncontrolling interestsTotal stockholders’ equity
AmountShares AmountShares
Balance as of December 31, 2023$131 130,741 $1,245 $241 $(1,205)(6,661)$(359)$165 $218 
Net earnings (losses)— — — (51)— — — 1 (50)
Other comprehensive (loss) income— — — — — — 204 — 204 
Dividends to Clorox stockholders ($1.20 per share declared)
— — — (150)— — — — (150)
Dividends to noncontrolling interests— — — — — — — (2)(2)
Stock-based compensation— — 26 — — — — — 26 
Other employee stock plan activities— — (1)(6)16 106 — — 9 
Balance as of March 31, 2024$131 130,741 $1,270 $34 $(1,189)(6,555)$(155)$164 $255 
Balance as of December 31, 2024$131 130,741 $1,287 $68 $(1,346)(7,591)$(181)$162 $121 
Net earnings— — — 186 — — — 5 191 
Other comprehensive (loss) income— — — — — — 5 — 5 
Dividends to Clorox stockholders ($1.22 per share declared)
— — — (152)— — — — (152)
Dividends to noncontrolling interests— — — — — — — (4)(4)
Stock-based compensation— — 24 — — — — — 24 
Other employee stock plan activities— — (7)(3)15 101 — — 5 
Treasury stock purchased— — — — — — — — — 
Balance as of March 31, 2025$131 130,741 $1,304 $99 $(1,331)(7,490)$(176)$163 $190 
Nine months ended March 31
(Dollars in millions except per share data; shares in thousands)
Common stock
Additional paid-in capital
Retained earnings
Treasury stock
Accumulated
other
comprehensive
net (loss) income
Noncontrolling interests
Total stockholders’ equity
AmountSharesAmountShares
Balance as of June 30, 2023$131 130,741 $1,245 $583 $(1,246)(6,921)$(493)$168 $388 
Net earnings— — — 64 — — — 7 71 
Other comprehensive (loss) income— — — — — — 338 — 338 
Dividends to Clorox stockholders ($4.80 per share declared)
— — — (600)— — — — (600)
Dividends to noncontrolling interests— — — — — — — (11)(11)
Stock-based compensation— — 55 — — — — — 55 
Other employee stock plan activities— — (30)(13)57 366 — — 14 
Balance as of March 31, 2024$131 130,741 $1,270 $34 $(1,189)(6,555)$(155)$164 $255 
Balance as of June 30, 2024$131 130,741 $1,288 $250 $(1,186)(6,540)$(155)$164 $492 
Net earnings— — — 478 — — — 10 488 
Other comprehensive (loss) income— — — — — — (21)— (21)
Dividends to Clorox stockholders ($4.88 per share declared)
— — — (609)— — — — (609)
Dividends to noncontrolling interests— — — — — — — (11)(11)
Stock-based compensation— — 64 — — — — — 64 
Other employee stock plan activities— — (48)(20)112 745 — — 44 
Treasury stock purchased— — — — (257)(1,695)— — (257)
Balance as of March 31, 2025$131 130,741 $1,304 $99 $(1,331)(7,490)$(176)$163 $190 
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:
Three months ended March 31
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of December 31, 2023$(439)$90 $(10)$(359)
Other comprehensive (loss) income before reclassifications(16)2 — (14)
Amounts reclassified from Accumulated other comprehensive net (loss) income (1)
223 (2)— 221 
Income tax benefit (expense)(1)(1)(1)(3)
Net current period other comprehensive (loss) income206 (1)(1)204 
Balance as of March 31, 2024$(233)$89 $(11)$(155)
Balance as of December 31, 2024
$(259)$80 $(2)$(181)
Other comprehensive (loss) income before reclassifications6 — — 6 
Amounts reclassified from Accumulated other comprehensive net (loss) income
— (2)— (2)
Income tax benefit (expense)
1 — — 1 
Net current period other comprehensive (loss) income7 (2)— 5 
Balance as of March 31, 2025$(252)$78 $(2)$(176)
Nine months ended March 31
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivatives
Pension and postretirement benefit adjustments
Accumulated other comprehensive net (loss) income
Balance as of June 30, 2023$(445)$99 $(147)$(493)
Other comprehensive (loss) income before reclassifications(10)(4)4 (10)
Amounts reclassified from Accumulated other comprehensive net (loss) income (1) (2)
223 (6)175 392 
Income tax benefit (expense)(1)— (43)(44)
Net current period other comprehensive (loss) income212 (10)136 338 
Balance as of March 31, 2024$(233)$89 $(11)$(155)
Balance as of June 30, 2024$(239)$85 $(1)$(155)
Other comprehensive (loss) income before reclassifications(14)(1)— (15)
Amounts reclassified from Accumulated other comprehensive net (loss) income
— (5)(1)(6)
Income tax benefit (expense)
1 (1)— — 
Net current period other comprehensive (loss) income(13)(7)(1)(21)
Balance as of March 31, 2025$(252)$78 $(2)$(176)
(1)Includes the release of currency translation adjustment from the Argentina business divestiture. See Note 3 for additional details.
v3.25.1
EMPLOYEE BENEFIT PLANS
 9 Months Ended
Mar. 31, 2025
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLANS EMPLOYEE BENEFIT PLANS
In the second quarter of fiscal year 2024, the Company settled plan benefits of its domestic qualified pension plan (the Plan) and recorded a one-time noncash charge, net of curtailment gain, of $171 before taxes ($130 after tax) in the Company’s condensed consolidated statement of earnings and comprehensive income.
The Company continues to maintain various other retirement income plans for eligible domestic and international employees.
The following table summarizes the components of net periodic benefit (credit) cost for the Company’s remaining retirement income plans:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Interest cost$1 $2 $4 $10 
Expected return on plan assets (1)
— — (1)(2)
Amortization of unrecognized items— — — 3 
Curtailment gain
— — — (6)
Settlement (gain) loss
2 — (2)178 
Total$3 $2 $1 $183 
(1)The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2025 net periodic benefit cost is 5.8%.
The net periodic benefit (credit) cost for the Company’s retirement health care plans was $0 and ($1) for the three and nine months ended March 31, 2025, respectively and ($1) for both the three and nine months ended March 31, 2024.
During both the three months ended March 31, 2025 and 2024, the Company made $8 in contributions to its domestic retirement income plans. During both the nine months ended March 31, 2025 and 2024, the Company made $12 in contributions to its domestic retirement income plans.
Service cost component of the net periodic benefit cost, if any, is reflected in employee benefit costs. All other components are reflected in Other (income) expense, net.
v3.25.1
OTHER CONTINGENCIES AND GUARANTEES
 9 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
OTHER CONTINGENCIES AND GUARANTEES OTHER CONTINGENCIES AND GUARANTEES
Contingencies
The Company is involved in certain environmental matters, including response actions at various locations. The Company recorded liabilities totaling $27 and $28 as of March 31, 2025 and June 30, 2024, respectively for its share of aggregate future remediation costs related to these matters.
One matter, which accounted for $12 of the recorded liability as of both March 31, 2025 and June 30, 2024, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing groundwater at the site and included estimates of the related costs. Following further discussions with the regulators in 2017, the Company recorded an undiscounted liability for costs estimated to be incurred over a 30-year period, based on one of the options in the Feasibility Study related to groundwater. In September 2021, as a result of an additional study and further discussions with regulators, the Company submitted a Soil Vapor Intrusion Report to the regulators. In January 2023, the regulators issued a new order directing the Company and the current property owner to conduct a Remedial Investigation and then prepare a Feasibility Study to evaluate and remediate impacts to soil, groundwater, soil vapor and indoor air. While the Company believes its latest estimates of remediation costs (including any related to soil, groundwater, soil vapor and indoor air impacts) are reasonable, the ultimate remediation requirements are not yet finalized and the regulators could require the Company to implement remediation actions for a longer period or take additional actions, which could include estimated undiscounted costs in the aggregate of up to approximately $28 over an estimated 30-year period, or require the Company to take different actions and incur additional costs.
Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability as of both March 31, 2025 and June 30, 2024. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing agreement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital
expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time.
The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements and the future availability of alternative clean-up technologies. From time to time, the Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements (including costs connected to the transition and unwinding of certain supply and manufacturing relationships), product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
Guarantees
In conjunction with divestitures and other transactions, the Company has provided certain indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
The Company had not recorded any material liabilities on the aforementioned guarantees as of both March 31, 2025 and June 30, 2024.
The Company was a party to letters of credit of $18 as of March 31, 2025, primarily related to its insurance carriers, of which $0 had been drawn upon.
v3.25.1
SEGMENT RESULTS
 9 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
SEGMENT RESULTS SEGMENT RESULTS
The Company operates through strategic business units (SBUs) which are organized into operating segments. Operating segments are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. Operating segments not aggregated into a reportable segment are reflected in Corporate and Other.
Corporate and Other includes certain non-allocated administrative costs and various other non-operating income and expenses. Assets in Corporate and Other include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes. Corporate and Other includes the results and the Better Health VMS business through the date of divestiture of September 10, 2024.
The principal measure of segment profitability used by management is segment adjusted earnings (losses) before interest and income taxes (segment adjusted EBIT). Segment adjusted EBIT is defined as earnings (losses) before income taxes excluding interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental charges and insurance recoveries related to the August 2023 cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability).
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings (losses) before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate and Other.
Net sales
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Health and Wellness$630 $609 $1,956 $1,833 
Household469 526 1,362 1,353 
Lifestyle306 315 964 947 
International263 310 796 891 
Reportable segment total
$1,668 $1,760 $5,078 $5,024 
Corporate and Other— 54 38 166 
Total$1,668 $1,814 $5,116 $5,190 
Segment adjusted EBIT
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Health and Wellness$169 $154 $597 $517 
Household61 74 169 162 
Lifestyle60 64 196 192 
International31 38 87 104 
Reportable segment total
$321 $330 $1,049 $975 
Corporate and Other(55)(70)(193)(238)
Total$266 $260 $856 $737 
Interest income2 4 7 21 
Interest expense(23)(22)(66)(69)
Loss on divestiture (1)
— (240)(118)(240)
Pension settlement charge (2)
— — — (171)
Cyberattack costs, net of insurance recoveries (3)
35 (8)70 (57)
Streamlined operating model (4)
— (10)— (13)
Digital capabilities and productivity enhancements investment (5)
(26)(26)(81)(85)
Earnings before income taxes
$254 $(42)$668 $123 
(1)Represents losses on divestiture of the Better Health VMS and Argentina businesses corresponding to Corporate and Other and International, respectively. See Note 3 for additional details related to the divestitures.
(2)Represents costs related to the settlement of the domestic qualified pension plan corresponding to Corporate and Other. See Note 15 for additional details related to the pension settlement.
(3)Represents insurance recoveries of $35 and $70 in the three and nine months ended March 31, 2025, respectively, and incremental expenses of approximately $8 and $57 in the three and nine months ended March 31, 2024, respectively, as a result of the cyberattack. See Note 4 for additional details related to the August 2023 cyberattack. For informational purposes, the following table provides the approximate cyberattack costs and insurance recoveries corresponding to the Company’s reportable segments as a percentage of the total:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Health and Wellness— %18 %— %15 %
Household— 12 — 11 
Lifestyle— — — 11 
International— — — 4 
Corporate and Other100 70 100 59 
Total100 %100 %100 %100 %
(4)Represents restructuring and related implementation costs, net for the streamlined operating model of $10 and $13 for the three and nine months ended March 31, 2024, respectively, primarily corresponding to Corporate and Other.
(5)Represents expenses related to the Company’s digital capabilities and productivity enhancements investment corresponding to Corporate and Other.
All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.
Net sales to the Company’s largest customer, Walmart Inc. and its affiliates, as a percentage of consolidated net sales, were 27% and 26% for the three and nine months ended March 31, 2025, respectively, and 25% for both the three and nine months ended March 31, 2024.
The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the periods indicated:
Net sales
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Cleaning33 %29 %33 %30 %
Professional Products5 5 5 5 
Health and Wellness38 %34 %38 %35 %
Bags and Wraps12 12 12 12 
Cat Litter8 8 9 9 
Grilling8 9 6 6 
Household28 %29 %27 %27 %
Food11 10 11 10 
Water Filtration4 4 4 4 
Natural Personal Care3 3 4 4 
Lifestyle18 %17 %19 %18 %
International16 %17 %15 %17 %
Corporate and Other— %3 %1 %3 %
Total100 %100 %100 %100 %
v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Pay vs Performance Disclosure        
Net Income (Loss) $ 186 $ (51) $ 478 $ 64
v3.25.1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The unaudited interim condensed consolidated financial statements for the three and nine months ended March 31, 2025 and 2024, in the opinion of management, reflect all normal and recurring adjustments considered necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company or Clorox) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. Percentage and basis point calculations are based on rounded numbers, except for per share data and the effective tax rate.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2024, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.
Recently Issued Accounting Standards
Recently Issued Accounting Standards
Recently Issued Accounting Standards Not Yet Adopted
In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” These amendments primarily require enhanced quantitative and qualitative disclosures in the notes to the financial statements for specific expense categories underlying the expenses presented on the income statement. These amendments are to be applied prospectively to financial statements issued after the effective date or retrospectively to any or all periods presented in the financial statements. Early adoption is permitted. The standard will be effective for annual periods beginning after December 15, 2026, and subsequent interim periods. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” These amendments primarily require enhanced disclosures and disaggregation of income tax information by jurisdiction in the annual income tax reconciliation and quantitative and qualitative disclosures regarding income taxes paid. These amendments are to be applied prospectively, with the option to apply the standard retrospectively, for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments primarily require enhanced disclosures about significant segment expenses regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. These amendments are to be applied retrospectively for all periods presented in the financial statements and will be effective for the annual period beginning July 1, 2024, and interim periods beginning July 1, 2025. The Company is currently evaluating the impact that the adoption of this guidance will have on the Company’s disclosures.
Recently Adopted Accounting Standards
In September 2022, the FASB issued ASU No. 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” These amendments require disclosure of the key terms of outstanding supplier finance programs and a rollforward of the related obligations. These amendments are effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted the standard as of July 1, 2023, except for the rollforward information which will be effective for the fiscal year ending June 30, 2025. The adoption relates to disclosures only and does not have an impact on the condensed consolidated financial statements, results of operations or cash flows.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.
As of both March 31, 2025 and June 30, 2024, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis during the period included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
Segment Results
The Company operates through strategic business units (SBUs) which are organized into operating segments. Operating segments are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. Operating segments not aggregated into a reportable segment are reflected in Corporate and Other.
Corporate and Other includes certain non-allocated administrative costs and various other non-operating income and expenses. Assets in Corporate and Other include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes. Corporate and Other includes the results and the Better Health VMS business through the date of divestiture of September 10, 2024.
The principal measure of segment profitability used by management is segment adjusted earnings (losses) before interest and income taxes (segment adjusted EBIT). Segment adjusted EBIT is defined as earnings (losses) before income taxes excluding interest income, interest expense and other significant items that are nonrecurring or unusual (such as the pension settlement charge, incremental charges and insurance recoveries related to the August 2023 cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions / divestitures and other nonrecurring or unusual items impacting comparability).
v3.25.1
DIVESTITURES (Tables)
 9 Months Ended
Mar. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Major Classes of Assets and Liabilities Divested and Net Sales of Divested Business
The major classes of assets and liabilities of the Better Health VMS business divested as of September 10, 2024 were as follows:
Divestiture
Working capital, net$41 
Property, plant and equipment, net59 
Trademarks, net
37 
Other intangible assets, net
58 
Other assets (1)
45 
Other liabilities(1)
Net assets divested$239 
(1) Includes net deferred tax assets of $45
The following table presents Net sales of the Better Health VMS business, which includes the financial results up to September 10, 2024, the date of sale:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Net sales
$— $54 $38 $166 
v3.25.1
AUGUST 2023 CYBERATTACK (Tables)
 9 Months Ended
Mar. 31, 2025
Unusual or Infrequent Items, or Both [Abstract]  
Schedule of Costs Recognized from Cyberattack The following table summarizes the recognition of (insurance recoveries) and costs in the condensed consolidated statements of earnings and comprehensive income:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Costs of products sold
$(2)$1 $(5)$21 
Selling and administrative expenses— 7 — 36 
Other (income) expense, net
(33)— (65)— 
Total$(35)$8 $(70)$57 
v3.25.1
RESTRUCTURING AND RELATED COSTS (Tables)
 9 Months Ended
Mar. 31, 2025
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring and Related Costs
The total restructuring and related implementation costs, net associated with the Company’s streamlined operating model as reflected in the condensed consolidated statements of earnings and comprehensive income:
Three months endedNine months ended
3/31/20243/31/2024
Selling and administrative expenses$5 $8 
Other (income) expense, net:
Employee-related costs$5 $5 
Total costs$10 $13 
Schedule of Restructuring Reserve by Type of Cost
The following table reconciles the accrual for the streamlined operating model’s restructuring and related implementation costs discussed above, which are recorded within Accounts payable and accrued liabilities in the condensed consolidated balance sheets:
Employee-Related CostsOtherTotal
Accrual Balance as of June 30, 2024
$8 $11 $19 
Cash payments(8)(11)(19)
Accrual Balance as of March 31, 2025$— $— $— 
v3.25.1
INVENTORIES, NET (Tables)
 9 Months Ended
Mar. 31, 2025
Inventory Disclosure [Abstract]  
Schedule of Inventories, Net
Inventories, net consisted of the following as of:
3/31/20256/30/2024
Finished goods$553 $556 
Raw materials and packaging145 172 
Work in process21 9 
LIFO allowances(84)(98)
Total inventories, net$635 $639 
Less: Non-current inventories, net (1)
— 2 
Total current inventories, net$635 $637 
(1)Non-current inventories, net are recorded in Other assets.
v3.25.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)
 9 Months Ended
Mar. 31, 2025
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]  
Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings (losses) were as follows:
Gains (losses) recognized in Other comprehensive (loss) income
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Commodity purchase derivative contracts$1 $— $(2)$(5)
Foreign exchange derivative contracts(1)2 1 1 
Total$— $2 $(1)$(4)
Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings
Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earningsGains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Commodity purchase derivative contractsCost of products sold$(2)$(2)$(5)$(4)
Interest rate derivative contractsInterest expense4 4 10 10 
Total$2 $2 $5 $6 
Schedule of Assets and Liabilities for Fair Value of Derivative Instruments and Fair Value Disclosure The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
 3/31/20256/30/2024
Balance sheet
classification		Fair value
hierarchy
level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Commodity purchase futures contracts
Prepaid expenses and other current assets1$1 $1 $— $— 
Commodity purchase swaps contractsPrepaid expenses and other current assets2— — 1 1 
Foreign exchange forward contractsPrepaid expenses and other current assets21 1 — — 
 $2 $2 $1 $1 
Liabilities
Commodity purchase futures contractsAccounts payable and accrued liabilities1$— $— $2 $2 
Commodity purchase swaps contractsAccounts payable and accrued liabilities21 1 — — 
$1 $1 $2 $2 
The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
 3/31/20256/30/2024
Balance sheet
classification		Fair value
hierarchy
level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Interest-bearing investments, including money market funds
Cash and cash
equivalents (1)
1$99 $99 $95 $95 
Time deposits
Cash and cash
equivalents (1)
214 14 9 9 
Trust assets for nonqualified deferred compensation plansOther assets1157 157 154 154 
 $270 $270 $258 $258 
Liabilities
Notes and loans payable
Notes and loans payable (2)
2$54 $54 $4 $4 
Long-term debt
Long-term debt (3)
22,483 2,407 2,481 2,341 
$2,537 $2,461 $2,485 $2,345 
(1)Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Notes and loans payable are composed of outstanding U.S. commercial paper balances and/or amounts drawn on the Company’s credit agreements, all of which are recorded at cost, which approximates fair value.
(3)Long-term debt is recorded at cost. The fair value of Long-term debt was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
v3.25.1
OTHER (INCOME) EXPENSE, NET (Tables)
 9 Months Ended
Mar. 31, 2025
Other Income and Expenses [Abstract]  
Major Components of Other (Income) Expense, Net
The major components of Other (income) expense, net were:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Amortization of trademarks and other intangible assets$5 $7 $16 $22 
Trust investment (gains) losses, net2 (8)(6)(18)
Net periodic benefit cost
3 1 — 11 
Foreign exchange transaction (gains) losses, net (1)
(1)1 2 24 
Income from equity investees— (1)(3)(3)
Interest income(2)(4)(7)(21)
Restructuring costs (2)
— 5 — 5 
Gain on sale-leaseback transaction (3)
— — — (16)
Cyberattack insurance recoveries (4)
(33)— (65)— 
Other(8)(3)(16)(1)
Total$(34)$(2)$(79)$3 
(1)Foreign exchange losses were primarily related to the Company’s operations in Argentina in the three and nine months ended March 31, 2024.
(2)Restructuring costs related to the implementation of the Company’s streamlined operating model. See Note 6 for additional details.
(3)On December 14, 2023, the Company completed an asset sale-leaseback transaction on a warehouse in Fairfield, California. The transaction resulted in a $16 gain which was recognized in Other (income) expense, net in the Health and Wellness segment. Refer to Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024 for further information related to the sale-leaseback transaction.
(4)Insurance recoveries related to the August 2023 cyberattack. See Note 4 for additional details.
v3.25.1
NET EARNINGS (LOSSES) PER SHARE (EPS) (Tables)
 9 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares Outstanding and Antidilutive Shares
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Basic123,367124,249123,643124,133
Dilutive effect of stock options and other699—825588
Diluted124,066124,249124,468124,721
Antidilutive stock options and other1,5754,758 1,575 2,720 
v3.25.1
COMPREHENSIVE INCOME (Tables)
 9 Months Ended
Mar. 31, 2025
Stockholders' Equity Note [Abstract]  
Schedule of Comprehensive Income
The following table provides a summary of Comprehensive income for the periods indicated:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Net earnings (losses)$191 $(50)$488 $71 
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments7 206 (13)212 
Net unrealized gains (losses) on derivatives(2)(1)(7)(10)
Pension and postretirement benefit adjustments— (1)(1)136 
Total other comprehensive (loss) income, net of tax5 204 (21)338 
Comprehensive income
196 154 467 409 
Less: Total comprehensive income attributable to noncontrolling interests5 1 10 7 
Total comprehensive income attributable to Clorox
$191 $153 $457 $402 
v3.25.1
STOCKHOLDERS' EQUITY (Tables)
 9 Months Ended
Mar. 31, 2025
Equity [Abstract]  
Schedule of Changes in Components of Stockholders’ Equity
Changes in the components of Stockholders’ equity were as follows for the periods indicated:
Three months ended March 31
(Dollars in millions except per share data; shares in thousands)
Common stockAdditional paid-in capitalRetained earningsTreasury stockAccumulated
other
comprehensive
net (loss) income		Noncontrolling interestsTotal stockholders’ equity
AmountShares AmountShares
Balance as of December 31, 2023$131 130,741 $1,245 $241 $(1,205)(6,661)$(359)$165 $218 
Net earnings (losses)— — — (51)— — — 1 (50)
Other comprehensive (loss) income— — — — — — 204 — 204 
Dividends to Clorox stockholders ($1.20 per share declared)
— — — (150)— — — — (150)
Dividends to noncontrolling interests— — — — — — — (2)(2)
Stock-based compensation— — 26 — — — — — 26 
Other employee stock plan activities— — (1)(6)16 106 — — 9 
Balance as of March 31, 2024$131 130,741 $1,270 $34 $(1,189)(6,555)$(155)$164 $255 
Balance as of December 31, 2024$131 130,741 $1,287 $68 $(1,346)(7,591)$(181)$162 $121 
Net earnings— — — 186 — — — 5 191 
Other comprehensive (loss) income— — — — — — 5 — 5 
Dividends to Clorox stockholders ($1.22 per share declared)
— — — (152)— — — — (152)
Dividends to noncontrolling interests— — — — — — — (4)(4)
Stock-based compensation— — 24 — — — — — 24 
Other employee stock plan activities— — (7)(3)15 101 — — 5 
Treasury stock purchased— — — — — — — — — 
Balance as of March 31, 2025$131 130,741 $1,304 $99 $(1,331)(7,490)$(176)$163 $190 
Nine months ended March 31
(Dollars in millions except per share data; shares in thousands)
Common stock
Additional paid-in capital
Retained earnings
Treasury stock
Accumulated
other
comprehensive
net (loss) income
Noncontrolling interests
Total stockholders’ equity
AmountSharesAmountShares
Balance as of June 30, 2023$131 130,741 $1,245 $583 $(1,246)(6,921)$(493)$168 $388 
Net earnings— — — 64 — — — 7 71 
Other comprehensive (loss) income— — — — — — 338 — 338 
Dividends to Clorox stockholders ($4.80 per share declared)
— — — (600)— — — — (600)
Dividends to noncontrolling interests— — — — — — — (11)(11)
Stock-based compensation— — 55 — — — — — 55 
Other employee stock plan activities— — (30)(13)57 366 — — 14 
Balance as of March 31, 2024$131 130,741 $1,270 $34 $(1,189)(6,555)$(155)$164 $255 
Balance as of June 30, 2024$131 130,741 $1,288 $250 $(1,186)(6,540)$(155)$164 $492 
Net earnings— — — 478 — — — 10 488 
Other comprehensive (loss) income— — — — — — (21)— (21)
Dividends to Clorox stockholders ($4.88 per share declared)
— — — (609)— — — — (609)
Dividends to noncontrolling interests— — — — — — — (11)(11)
Stock-based compensation— — 64 — — — — — 64 
Other employee stock plan activities— — (48)(20)112 745 — — 44 
Treasury stock purchased— — — — (257)(1,695)— — (257)
Balance as of March 31, 2025$131 130,741 $1,304 $99 $(1,331)(7,490)$(176)$163 $190 
Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:
Three months ended March 31
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of December 31, 2023$(439)$90 $(10)$(359)
Other comprehensive (loss) income before reclassifications(16)2 — (14)
Amounts reclassified from Accumulated other comprehensive net (loss) income (1)
223 (2)— 221 
Income tax benefit (expense)(1)(1)(1)(3)
Net current period other comprehensive (loss) income206 (1)(1)204 
Balance as of March 31, 2024$(233)$89 $(11)$(155)
Balance as of December 31, 2024
$(259)$80 $(2)$(181)
Other comprehensive (loss) income before reclassifications6 — — 6 
Amounts reclassified from Accumulated other comprehensive net (loss) income
— (2)— (2)
Income tax benefit (expense)
1 — — 1 
Net current period other comprehensive (loss) income7 (2)— 5 
Balance as of March 31, 2025$(252)$78 $(2)$(176)
Nine months ended March 31
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivatives
Pension and postretirement benefit adjustments
Accumulated other comprehensive net (loss) income
Balance as of June 30, 2023$(445)$99 $(147)$(493)
Other comprehensive (loss) income before reclassifications(10)(4)4 (10)
Amounts reclassified from Accumulated other comprehensive net (loss) income (1) (2)
223 (6)175 392 
Income tax benefit (expense)(1)— (43)(44)
Net current period other comprehensive (loss) income212 (10)136 338 
Balance as of March 31, 2024$(233)$89 $(11)$(155)
Balance as of June 30, 2024$(239)$85 $(1)$(155)
Other comprehensive (loss) income before reclassifications(14)(1)— (15)
Amounts reclassified from Accumulated other comprehensive net (loss) income
— (5)(1)(6)
Income tax benefit (expense)
1 (1)— — 
Net current period other comprehensive (loss) income(13)(7)(1)(21)
Balance as of March 31, 2025$(252)$78 $(2)$(176)
(1)Includes the release of currency translation adjustment from the Argentina business divestiture. See Note 3 for additional details.
(2)Includes recognition of pension settlement charge reclassified into Net earnings. See Note 15 for additional details.
v3.25.1
EMPLOYEE BENEFIT PLANS (Tables)
 9 Months Ended
Mar. 31, 2025
Retirement Benefits [Abstract]  
Schedule of Components of Net Periodic Benefit (Credit ) Cost
The following table summarizes the components of net periodic benefit (credit) cost for the Company’s remaining retirement income plans:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Interest cost$1 $2 $4 $10 
Expected return on plan assets (1)
— — (1)(2)
Amortization of unrecognized items— — — 3 
Curtailment gain
— — — (6)
Settlement (gain) loss
2 — (2)178 
Total$3 $2 $1 $183 
(1)The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2025 net periodic benefit cost is 5.8%.
v3.25.1
SEGMENT RESULTS (Tables)
 9 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Reportable Segment Information
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings (losses) before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate and Other.
Net sales
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Health and Wellness$630 $609 $1,956 $1,833 
Household469 526 1,362 1,353 
Lifestyle306 315 964 947 
International263 310 796 891 
Reportable segment total
$1,668 $1,760 $5,078 $5,024 
Corporate and Other— 54 38 166 
Total$1,668 $1,814 $5,116 $5,190 
Segment adjusted EBIT
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Health and Wellness$169 $154 $597 $517 
Household61 74 169 162 
Lifestyle60 64 196 192 
International31 38 87 104 
Reportable segment total
$321 $330 $1,049 $975 
Corporate and Other(55)(70)(193)(238)
Total$266 $260 $856 $737 
Interest income2 4 7 21 
Interest expense(23)(22)(66)(69)
Loss on divestiture (1)
— (240)(118)(240)
Pension settlement charge (2)
— — — (171)
Cyberattack costs, net of insurance recoveries (3)
35 (8)70 (57)
Streamlined operating model (4)
— (10)— (13)
Digital capabilities and productivity enhancements investment (5)
(26)(26)(81)(85)
Earnings before income taxes
$254 $(42)$668 $123 
(1)Represents losses on divestiture of the Better Health VMS and Argentina businesses corresponding to Corporate and Other and International, respectively. See Note 3 for additional details related to the divestitures.
(2)Represents costs related to the settlement of the domestic qualified pension plan corresponding to Corporate and Other. See Note 15 for additional details related to the pension settlement.
(3)Represents insurance recoveries of $35 and $70 in the three and nine months ended March 31, 2025, respectively, and incremental expenses of approximately $8 and $57 in the three and nine months ended March 31, 2024, respectively, as a result of the cyberattack. See Note 4 for additional details related to the August 2023 cyberattack. For informational purposes, the following table provides the approximate cyberattack costs and insurance recoveries corresponding to the Company’s reportable segments as a percentage of the total:
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Health and Wellness— %18 %— %15 %
Household— 12 — 11 
Lifestyle— — — 11 
International— — — 4 
Corporate and Other100 70 100 59 
Total100 %100 %100 %100 %
(4)Represents restructuring and related implementation costs, net for the streamlined operating model of $10 and $13 for the three and nine months ended March 31, 2024, respectively, primarily corresponding to Corporate and Other.
(5)Represents expenses related to the Company’s digital capabilities and productivity enhancements investment corresponding to Corporate and Other.
Schedule of Net Sales Percentages
The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the periods indicated:
Net sales
Three months endedNine months ended
3/31/20253/31/20243/31/20253/31/2024
Cleaning33 %29 %33 %30 %
Professional Products5 5 5 5 
Health and Wellness38 %34 %38 %35 %
Bags and Wraps12 12 12 12 
Cat Litter8 8 9 9 
Grilling8 9 6 6 
Household28 %29 %27 %27 %
Food11 10 11 10 
Water Filtration4 4 4 4 
Natural Personal Care3 3 4 4 
Lifestyle18 %17 %19 %18 %
International16 %17 %15 %17 %
Corporate and Other— %3 %1 %3 %
Total100 %100 %100 %100 %
v3.25.1
VENTURE AGREEMENT (Details) - USD ($)
$ in Millions
 9 Months Ended
Mar. 31, 2025
Jun. 30, 2024
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]    
Option to extend agreement (in years) 7 years  
Venture agreement, terminal obligation $ 476 $ 531
Venture agreement terminal obligation, net $ 515 $ 510
Glad Business    
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]    
Percent ownership by venture partner 20.00% 20.00%
v3.25.1
DIVESTITURES - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Loss on divestiture $ 0 $ 240 $ 118 $ 240
Vitamins, Minerals and Supplements Business | Disposal Group, Disposed of by Sale, Not Discontinued Operations        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Loss on divestiture     118  
Net sales $ 0 54 $ 38 166
Argentina Business | Disposal Group, Disposed of by Sale, Not Discontinued Operations        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Loss on divestiture   240   240
Net sales   $ 43   $ 123
v3.25.1
DIVESTITURES - Schedule of Major Classes of Assets and Liabilities Divested (Details) - Vitamins, Minerals and Supplements Business - Disposal Group, Disposed of by Sale, Not Discontinued Operations
$ in Millions
Mar. 31, 2025
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Working capital, net $ 41
Property, plant and equipment, net 59
Trademarks, net 37
Other intangible assets, net 58
Other assets 45
Other liabilities (1)
Net assets divested 239
Deferred tax assets $ 45
v3.25.1
DIVESTITURES - Schedule of Net Sales of Divested Business (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Vitamins, Minerals and Supplements Business | Disposal Group, Disposed of by Sale, Not Discontinued Operations        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Net sales $ 0 $ 54 $ 38 $ 166
v3.25.1
AUGUST 2023 CYBERATTACK - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Unusual or Infrequent Item, or Both [Line Items]        
Insurance proceeds, net of expenses $ 33 $ 0 $ 65 $ 0
August 2023 Cyberattack        
Unusual or Infrequent Item, or Both [Line Items]        
Insurance proceeds, net of expenses $ 35 $ (8) $ 70 $ (57)
v3.25.1
AUGUST 2023 CYBERATTACK - Schedule of Costs Recognized from Cyberattack (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Unusual or Infrequent Item, or Both [Line Items]        
Insurance proceeds, net of expenses $ (33) $ 0 $ (65) $ 0
August 2023 Cyberattack        
Unusual or Infrequent Item, or Both [Line Items]        
Insurance proceeds, net of expenses (35) 8 (70) 57
Costs of products sold | August 2023 Cyberattack        
Unusual or Infrequent Item, or Both [Line Items]        
Insurance proceeds, net of expenses (2) 1 (5) 21
Selling and administrative expenses | August 2023 Cyberattack        
Unusual or Infrequent Item, or Both [Line Items]        
Insurance proceeds, net of expenses 0 7 0 36
Other (income) expense, net | August 2023 Cyberattack        
Unusual or Infrequent Item, or Both [Line Items]        
Insurance proceeds, net of expenses $ (33) $ 0 $ (65) $ 0
v3.25.1
SUPPLY CHAIN FINANCING PROGRAM (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Jun. 30, 2024
Supplier Finance Program [Line Items]    
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration] Accounts payable and accrued liabilities Accounts payable and accrued liabilities
Amount due to suppliers participating in SCF $ 227 $ 205
Maximum    
Supplier Finance Program [Line Items]    
SCF payment term 120 days  
v3.25.1
RESTRUCTURING AND RELATED COSTS - Schedule of Total Restructuring and Related Implementation Costs (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Restructuring Cost and Reserve [Line Items]        
Total costs $ 0 $ 10 $ 0 $ 13
Selling and administrative expenses        
Restructuring Cost and Reserve [Line Items]        
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]   Selling and administrative expenses   Selling and administrative expenses
Total costs   $ 5   $ 8
Other (income) expense, net:        
Restructuring Cost and Reserve [Line Items]        
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]   Other (income) expense, net   Other (income) expense, net
Other (income) expense, net: | Employee-related costs        
Restructuring Cost and Reserve [Line Items]        
Total costs   $ 5   $ 5
v3.25.1
RESTRUCTURING AND RELATED COSTS - Schedule of Restructuring and Related Implementation Costs (Details)
$ in Millions
 9 Months Ended
Mar. 31, 2025
USD ($)
Restructuring Reserve [Roll Forward]  
Beginning balance $ 19
Cash payments (19)
Ending balance 0
Employee-Related Costs  
Restructuring Reserve [Roll Forward]  
Beginning balance 8
Cash payments (8)
Ending balance 0
Other  
Restructuring Reserve [Roll Forward]  
Beginning balance 11
Cash payments (11)
Ending balance $ 0
v3.25.1
INVENTORIES, NET (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Jun. 30, 2024
Inventory Disclosure [Abstract]    
Finished goods $ 553 $ 556
Raw materials and packaging 145 172
Work in process 21 9
LIFO allowances (84) (98)
Total inventories, net 635 639
Less: Non-current inventories, net 0 2
Total current inventories, net $ 635 $ 637
v3.25.1
DEBT (Details) - USD ($)
Mar. 31, 2025
Mar. 25, 2025
Jun. 30, 2024
Mar. 31, 2022
Line of Credit Facility [Line Items]        
Weighted average effective interest rate of notes and loans payable, percent 4.59%   5.60%  
Revolving Credit Facility | Credit Agreement        
Line of Credit Facility [Line Items]        
Line of credit facility, borrowing capacity   $ 1,200,000,000    
Termination fees/penalties   $ 0    
Line of credit facility, amount outstanding $ 0   $ 0  
Revolving Credit Facility | Prior Credit Agreement        
Line of Credit Facility [Line Items]        
Line of credit facility, borrowing capacity       $ 1,200,000,000
Line of credit facility, amount outstanding $ 0   $ 0  
v3.25.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($)
 9 Months Ended
Mar. 31, 2025
Jun. 30, 2024
Derivative [Line Items]    
Maximum duration, foreign exchange contracts (in years) 2 years  
Maximum duration, interest rate contracts (in years) 3 years  
Estimated amount of the existing net gain (loss) to be reclassified into earnings in the next 12 months $ 12,000,000  
Amount of derivative instruments subject to contractually defined counterparty liability position limits 0 $ 0
Interest rate contracts    
Derivative [Line Items]    
Notional amount of derivatives 0 0
Commodity purchase derivative contracts    
Derivative [Line Items]    
Cash margin balances amount 1,000,000 3,000,000
Purchases of Inventory | Foreign exchange derivative contracts    
Derivative [Line Items]    
Notional amount of derivatives $ 37,000,000 29,000,000
Total Commodity Purchase Derivative Contracts    
Derivative [Line Items]    
Maximum duration, commodity contracts (in years) 2 years  
Notional amount of derivatives $ 27,000,000 $ 38,000,000
v3.25.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Effects of Derivative Instruments Designated as Hedging Instruments on OCI and Net Earnings (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) recognized in Other comprehensive (loss) income $ 0 $ 2 $ (1) $ (4)
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings 2 2 5 6
Commodity purchase derivative contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) recognized in Other comprehensive (loss) income 1 0 (2) (5)
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings (2) (2) (5) (4)
Foreign exchange derivative contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) recognized in Other comprehensive (loss) income (1) 2 1 1
Interest rate derivative contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings $ 4 $ 4 $ 10 $ 10
v3.25.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Assets and Liabilities for Fair Value of Derivative Instruments (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Jun. 30, 2024
Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets $ 2 $ 1
Liabilities 1 2
Estimated Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 2 1
Liabilities 1 2
Commodity purchase derivative contracts | Level 2 | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0 1
Liabilities 1 0
Commodity purchase derivative contracts | Level 2 | Estimated Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 0 1
Liabilities 1 0
Commodity purchase derivative contracts | Level 1 | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 1 0
Liabilities 0 2
Commodity purchase derivative contracts | Level 1 | Estimated Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 1 0
Liabilities 0 2
Foreign exchange forward contract | Level 2 | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets 1 0
Foreign exchange forward contract | Level 2 | Estimated Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets $ 1 $ 0
v3.25.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Assets and Liabilities for Fair Value Disclosure (Details) - USD ($)
$ in Millions
Mar. 31, 2025
Jun. 30, 2024
Assets    
Cash and cash equivalents $ 226 $ 202
Total assets 5,512 5,751
Liabilities    
Notes and loans payable 54 4
Total liabilities 5,322 5,259
Carrying Amount    
Assets    
Total assets 270 258
Liabilities    
Total liabilities 2,537 2,485
Estimated Fair Value    
Assets    
Total assets, estimated fair value 270 258
Liabilities    
Total liabilities, estimated fair value 2,461 2,345
Level 1 | Carrying Amount    
Assets    
Trust assets for nonqualified deferred compensation plans 157 154
Level 1 | Estimated Fair Value    
Assets    
Trust assets for nonqualified deferred compensation plans, estimated fair value 157 154
Level 2 | Carrying Amount | Long-term debt    
Liabilities    
Long-term debt 2,483 2,481
Level 2 | Carrying Amount | Notes and loans payable    
Liabilities    
Notes and loans payable 54 4
Level 2 | Estimated Fair Value | Long-term debt    
Liabilities    
Long-term debt, estimated fair value 2,407 2,341
Level 2 | Estimated Fair Value | Notes and loans payable    
Liabilities    
Notes and loans payable, estimated fair value 54 4
Interest-bearing investments, including money market funds | Level 1 | Carrying Amount    
Assets    
Cash and cash equivalents 99 95
Interest-bearing investments, including money market funds | Level 1 | Estimated Fair Value    
Assets    
Cash and cash equivalents, estimated fair value 99 95
Time deposits | Level 2 | Carrying Amount    
Assets    
Cash and cash equivalents 14 9
Time deposits | Level 2 | Estimated Fair Value    
Assets    
Cash and cash equivalents, estimated fair value $ 14 $ 9
v3.25.1
OTHER (INCOME) EXPENSE, NET (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Dec. 14, 2023
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Other Income and Expenses [Abstract]          
Amortization of trademarks and other intangible assets   $ 5 $ 7 $ 16 $ 22
Trust investment (gains) losses, net   2 (8) (6) (18)
Net periodic benefit cost   3 1 0 11
Foreign exchange transaction (gains) losses, net   (1) 1 2 24
Income from equity investees   0 (1) (3) (3)
Interest income   (2) (4) (7) (21)
Restructuring costs   0 5 0 5
Gain on sale-leaseback transaction   0 0 0 (16)
Cyberattack insurance recoveries   33 0 65 0
Other   (8) (3) (16) (1)
Total   (34) (2) (79) 3
Segment Reporting Information [Line Items]          
Gain on sale-leaseback transaction   $ 0 $ 0 $ 0 $ 16
Health and Wellness          
Other Income and Expenses [Abstract]          
Gain on sale-leaseback transaction $ (16)        
Segment Reporting Information [Line Items]          
Gain on sale-leaseback transaction $ 16        
v3.25.1
INCOME TAXES (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Income Tax Disclosure [Abstract]        
Effective tax rate on earnings 24.80% (18.60%) 26.90% 41.90%
Income taxes paid, net of refunds     $ 208 $ 314
v3.25.1
NET EARNINGS (LOSSES) PER SHARE (EPS) (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Earnings Per Share [Abstract]        
Basic (in shares) 123,367 124,249 123,643 124,133
Dilutive effect of stock options and other (in shares) 699 0 825 588
Diluted (in shares) 124,066 124,249 124,468 124,721
Antidilutive stock options and other (in shares) 1,575 4,758 1,575 2,720
v3.25.1
COMPREHENSIVE INCOME (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Stockholders' Equity Note [Abstract]        
Net earnings (losses) $ 191 $ (50) $ 488 $ 71
Other comprehensive income (loss), net of tax:        
Foreign currency translation adjustments 7 206 (13) 212
Net unrealized gains (losses) on derivatives (2) (1) (7) (10)
Pension and postretirement benefit adjustments 0 (1) (1) 136
Total other comprehensive (loss) income, net of tax 5 204 (21) 338
Comprehensive income 196 154 467 409
Less: Total comprehensive income attributable to noncontrolling interests 5 1 10 7
Total comprehensive income attributable to Clorox $ 191 $ 153 $ 457 $ 402
v3.25.1
STOCKHOLDERS' EQUITY - Schedule of Changes in Components of Stockholders’ Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance $ 121 $ 218 $ 492 $ 388
Beginning balance, common stock (in shares)     124,201,807  
Beginning balance, treasury stock (in shares)     (6,539,654)  
Net earnings (losses) 191 (50) $ 488 71
Other comprehensive (loss) income 5 204 (21) 338
Dividends to Clorox stockholders (152) (150) (609) (600)
Dividends to noncontrolling interests (4) (2) (11) (11)
Stock-based compensation 24 26 64 55
Other employee stock plan activities 5 9 44 14
Treasury stock purchased 0   (257)  
Ending balance $ 190 $ 255 $ 190 $ 255
Ending balance, common stock (in shares) 123,251,595   123,251,595  
Ending balance, treasury stock (in shares) (7,489,866)   (7,489,866)  
Dividends declared per share (in dollars per share) $ 1.22 $ 1.20 $ 4.88 $ 4.80
Common stock        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance $ 131 $ 131 $ 131 $ 131
Beginning balance, common stock (in shares) 130,741,000 130,741,000 130,741,000 130,741,000
Ending balance $ 131 $ 131 $ 131 $ 131
Ending balance, common stock (in shares) 130,741,000 130,741,000 130,741,000 130,741,000
Additional paid-in capital        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance $ 1,287 $ 1,245 $ 1,288 $ 1,245
Stock-based compensation 24 26 64 55
Other employee stock plan activities (7) (1) (48) (30)
Ending balance 1,304 1,270 1,304 1,270
Retained earnings        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance 68 241 250 583
Net earnings (losses) 186 (51) 478 64
Dividends to Clorox stockholders (152) (150) (609) (600)
Other employee stock plan activities (3) (6) (20) (13)
Ending balance 99 34 99 34
Treasury stock        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance $ (1,346) $ (1,205) $ (1,186) $ (1,246)
Beginning balance, treasury stock (in shares) (7,591,000) (6,661,000) (6,540,000) (6,921,000)
Other employee stock plan activities $ 15 $ 16 $ 112 $ 57
Other employee stock plan activities (in shares) 101,000 106,000 745,000 366,000
Treasury stock purchased     $ (257)  
Treasury stock purchased (in shares)     (1,695,000)  
Ending balance $ (1,331) $ (1,189) $ (1,331) $ (1,189)
Ending balance, treasury stock (in shares) (7,490,000) (6,555,000) (7,490,000) (6,555,000)
Accumulated other comprehensive net (loss) income        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance $ (181) $ (359) $ (155) $ (493)
Other comprehensive (loss) income 5 204 (21) 338
Ending balance (176) (155) (176) (155)
Noncontrolling interests        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Beginning balance 162 165 164 168
Net earnings (losses) 5 1 10 7
Dividends to noncontrolling interests (4) (2) (11) (11)
Ending balance $ 163 $ 164 $ 163 $ 164
v3.25.1
STOCKHOLDERS' EQUITY - Schedule of Changes in Accumulated Other Comprehensive Net (Loss) Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Beginning balance     $ 328  
Total other comprehensive (loss) income, net of tax $ 5 $ 204 (21) $ 338
Ending balance 27   27  
Accumulated other comprehensive net (loss) income        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Beginning balance (181) (359) (155) (493)
Other comprehensive (loss) income before reclassifications 6 (14) (15) (10)
Amounts reclassified from Accumulated other comprehensive net (loss) income (2) 221 (6) 392
Income tax benefit (expense) 1 (3) 0 (44)
Total other comprehensive (loss) income, net of tax 5 204 (21) 338
Ending balance (176) (155) (176) (155)
Foreign currency translation adjustments        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Beginning balance (259) (439) (239) (445)
Other comprehensive (loss) income before reclassifications 6 (16) (14) (10)
Amounts reclassified from Accumulated other comprehensive net (loss) income 0 223 0 223
Income tax benefit (expense) 1 (1) 1 (1)
Total other comprehensive (loss) income, net of tax 7 206 (13) 212
Ending balance (252) (233) (252) (233)
Net unrealized gains (losses) on derivatives        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Beginning balance 80 90 85 99
Other comprehensive (loss) income before reclassifications 0 2 (1) (4)
Amounts reclassified from Accumulated other comprehensive net (loss) income (2) (2) (5) (6)
Income tax benefit (expense) 0 (1) (1) 0
Total other comprehensive (loss) income, net of tax (2) (1) (7) (10)
Ending balance 78 89 78 89
Pension and postretirement benefit adjustments        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Beginning balance (2) (10) (1) (147)
Other comprehensive (loss) income before reclassifications 0 0 0 4
Amounts reclassified from Accumulated other comprehensive net (loss) income 0 0 (1) 175
Income tax benefit (expense) 0 (1) 0 (43)
Total other comprehensive (loss) income, net of tax 0 (1) (1) 136
Ending balance $ (2) $ (11) $ (2) $ (11)
v3.25.1
EMPLOYEE BENEFIT PLANS - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2025
Mar. 31, 2024
Defined Benefit Plan Disclosure [Line Items]          
One-time noncash settlement charge, net of curtailment gain $ 0 $ 0   $ 0 $ 171
Net periodic benefit cost 3 1   0 11
Retirement Health Care          
Defined Benefit Plan Disclosure [Line Items]          
Net periodic benefit cost 0 (1)   (1) (1)
UNITED STATES | Retirement Income          
Defined Benefit Plan Disclosure [Line Items]          
One-time noncash settlement charge, net of curtailment gain     $ 171    
One-time noncash settlement charge, net of curtailment gain, after tax     $ 130    
Retirement plan contributions $ 8 $ 8   $ 12 $ 12
v3.25.1
EMPLOYEE BENEFIT PLANS - Schedule of Components of Net Periodic Benefit (Credit) Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Defined Benefit Plan Disclosure [Line Items]        
Total $ 3 $ 1 $ 0 $ 11
UNITED STATES | Retirement Income        
Defined Benefit Plan Disclosure [Line Items]        
Weighted average long-term expected rate or return on plan assets (percentage)     5.80%  
UNITED STATES | Retirement Income | Retirement Income Plans        
Defined Benefit Plan Disclosure [Line Items]        
Interest cost 1 2 $ 4 10
Expected return on plan assets 0 0 (1) (2)
Amortization of unrecognized items 0 0 0 3
Curtailment gain 0 0 0 (6)
Settlement (gain) loss 2 0 (2) 178
Total $ 3 $ 2 $ 1 $ 183
v3.25.1
OTHER CONTINGENCIES AND GUARANTEES (Details) - USD ($)
$ in Millions
 9 Months Ended
Mar. 31, 2025
Jun. 30, 2024
Loss Contingencies [Line Items]    
Liability for aggregate future remediation costs $ 27 $ 28
Letters of credit 18  
Letters of credit, amount outstanding 0  
Alameda County, California Matter    
Loss Contingencies [Line Items]    
Liability for aggregate future remediation costs $ 12 12
Remediation period (in years) 30 years  
Maximum undiscounted costs $ 28  
Dickinson County, Michigan Matter    
Loss Contingencies [Line Items]    
Liability for aggregate future remediation costs $ 10 $ 10
Remediation period (in years) 30 years  
Percentage of liability for aggregate remediation and associated costs, other than legal fees 24.30%  
v3.25.1
SEGMENT RESULTS - Narrative (Details) - segment
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Concentration Risk [Line Items]        
Number of reportable segments     4  
Revenue from Contract with Customer | Customer Concentration Risk | Walmart Stores, Inc.        
Concentration Risk [Line Items]        
Concentration percentage 27.00% 25.00% 26.00% 25.00%
v3.25.1
SEGMENT RESULTS - Schedule of Reportable Segment Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]        
Net sales $ 1,668 $ 1,814 $ 5,116 $ 5,190
Interest income 2 4 7 21
Interest expense (23) (22) (66) (69)
Loss on divestiture 0 (240) (118) (240)
Pension settlement charge 0 0 0 (171)
Cyberattack costs, net of insurance recoveries 35 (8) 70 (57)
Streamlined operating model 0 (10) 0 (13)
Digital capabilities and productivity enhancements investment (26) (26) (81) (85)
Earnings (losses) before income taxes 254 (42) 668 123
Insurance proceeds, net of expenses 33 0 65 0
August 2023 Cyberattack        
Segment Reporting Information [Line Items]        
Insurance proceeds, net of expenses $ 35 $ (8) $ 70 $ (57)
August 2023 Cyberattack | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 100.00% 100.00% 100.00% 100.00%
Operating Segments        
Segment Reporting Information [Line Items]        
Net sales $ 1,668 $ 1,760 $ 5,078 $ 5,024
Segment adjusted EBIT 321 330 1,049 975
Operating Segments | Health and Wellness        
Segment Reporting Information [Line Items]        
Net sales 630 609 1,956 1,833
Segment adjusted EBIT $ 169 $ 154 $ 597 $ 517
Operating Segments | Health and Wellness | August 2023 Cyberattack | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 0.00% 18.00% 0.00% 15.00%
Operating Segments | Household        
Segment Reporting Information [Line Items]        
Net sales $ 469 $ 526 $ 1,362 $ 1,353
Segment adjusted EBIT $ 61 $ 74 $ 169 $ 162
Operating Segments | Household | August 2023 Cyberattack | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 0.00% 12.00% 0.00% 11.00%
Operating Segments | Lifestyle        
Segment Reporting Information [Line Items]        
Net sales $ 306 $ 315 $ 964 $ 947
Segment adjusted EBIT $ 60 $ 64 $ 196 $ 192
Operating Segments | Lifestyle | August 2023 Cyberattack | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 0.00% 0.00% 0.00% 11.00%
Operating Segments | International        
Segment Reporting Information [Line Items]        
Net sales $ 263 $ 310 $ 796 $ 891
Segment adjusted EBIT $ 31 $ 38 $ 87 $ 104
Operating Segments | International | August 2023 Cyberattack | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 0.00% 0.00% 0.00% 4.00%
Corporate and Other        
Segment Reporting Information [Line Items]        
Net sales $ 0 $ 54 $ 38 $ 166
Segment adjusted EBIT $ (55) $ (70) $ (193) $ (238)
Corporate and Other | August 2023 Cyberattack | Product Concentration Risk        
Segment Reporting Information [Line Items]        
Concentration percentage 100.00% 70.00% 100.00% 59.00%
Operating Segments and Corporate and Other        
Segment Reporting Information [Line Items]        
Segment adjusted EBIT $ 266 $ 260 $ 856 $ 737
v3.25.1
SEGMENT RESULTS - Schedule of Net Sales Percentages (Details) - Revenue from Contract with Customer - Product Concentration Risk
 3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]        
Concentration percentage 100.00% 100.00% 100.00% 100.00%
Operating Segments | Health and Wellness        
Segment Reporting Information [Line Items]        
Concentration percentage 38.00% 34.00% 38.00% 35.00%
Operating Segments | Health and Wellness | Cleaning        
Segment Reporting Information [Line Items]        
Concentration percentage 33.00% 29.00% 33.00% 30.00%
Operating Segments | Health and Wellness | Professional Products        
Segment Reporting Information [Line Items]        
Concentration percentage 5.00% 5.00% 5.00% 5.00%
Operating Segments | Household        
Segment Reporting Information [Line Items]        
Concentration percentage 28.00% 29.00% 27.00% 27.00%
Operating Segments | Household | Bags and Wraps        
Segment Reporting Information [Line Items]        
Concentration percentage 12.00% 12.00% 12.00% 12.00%
Operating Segments | Household | Cat Litter        
Segment Reporting Information [Line Items]        
Concentration percentage 8.00% 8.00% 9.00% 9.00%
Operating Segments | Household | Grilling        
Segment Reporting Information [Line Items]        
Concentration percentage 8.00% 9.00% 6.00% 6.00%
Operating Segments | Lifestyle        
Segment Reporting Information [Line Items]        
Concentration percentage 18.00% 17.00% 19.00% 18.00%
Operating Segments | Lifestyle | Food        
Segment Reporting Information [Line Items]        
Concentration percentage 11.00% 10.00% 11.00% 10.00%
Operating Segments | Lifestyle | Water Filtration        
Segment Reporting Information [Line Items]        
Concentration percentage 4.00% 4.00% 4.00% 4.00%
Operating Segments | Lifestyle | Natural Personal Care        
Segment Reporting Information [Line Items]        
Concentration percentage 3.00% 3.00% 4.00% 4.00%
Operating Segments | International        
Segment Reporting Information [Line Items]        
Concentration percentage 16.00% 17.00% 15.00% 17.00%
Corporate and Other        
Segment Reporting Information [Line Items]        
Concentration percentage 0.00% 3.00% 1.00% 3.00%